Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.56 |
| ▸ | ELOC | Q15369 | 16/20 | 0.56 |
| ▸ | ELOB | Q15370 | 16/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24514420 | 1.00 | VHL (0.56) | VHLELOCELOB | |
| SCHEMBL23810801 | 0.90 | VHL (0.57) | VHLELOCELOB | |
| SCHEMBL23810800 | 0.90 | VHL (0.57) | VHLELOCELOB | |
| SCHEMBL24514607 | 0.87 | VHL (0.51) | VHLELOCELOB | |
| SCHEMBL29704345 | 0.87 | VHL (0.51) | VHLELOCELOB | |
| SCHEMBL24514425 | 0.86 | VHL (0.66) | VHLELOCELOB | |
| SCHEMBL30772103 | 0.86 | VHL (0.51) | VHLELOCELOB | |
| SCHEMBL24838322 | 0.84 | VHL (0.55) | VHLELOCELOB | |
| SCHEMBL24837824 | 0.84 | VHL (0.53) | VHLELOCELOB | |
| SCHEMBL23098441 | 0.83 | VHL (0.80) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606568-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4259144-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606568-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCD1, SMARCC1 | VHL 701/4885ELOC 1687/4885ELOB 1562/4885 |
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | VHL 264/4885ELOC 628/4885ELOB 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.